Discontinue use at 1st appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Patients w/ history of GI disease. Monitor patients w/ GI symptoms. W/draw use if GI ulceration or bleeding occurs. Patients receiving treatment w/ anticoagulants. Patients w/ CV disease or its risk factors. May precipitate overt renal decompensation which is typically followed by recovery to pre-treatment state upon discontinuation of NSAID therapy in patients whose renal blood flow & vol is decreased. Dehydrated patients, those w/ CHF, liver cirrhosis, nephrotic syndrome & overt renal disease, those receiving concomitant treatment w/ diuretic, ACE inhibitor, AIIA or those having undergone major surgical procedures which led to hypovolaemia; carefully monitor renal function including vol of diuresis at beginning of therapy. May rarely cause interstitial nephritis, glomerulonephritis, renal medullary necrosis or nephrotic syndrome. Discontinue use & carry out follow-up tests if abnormality (eg, elevated serum transaminases or other liver function parameters) is significant or persistent. Carefully supervise frail or debilitated patients. Induction of Na, K & water retention & interference w/ natriuretic effects of diuretics may occur. May precipitate or exacerbate cardiac failure or HTN in susceptible patients; clinical monitoring is recommended. May mask symptoms of underlying infectious disease. Contains Na 1 mmol/tab & lactose monohydrate 47 mg/max recommended daily dose. Not to be taken by patients w/ rare hereditary conditions of galactose intolerance (eg, galactosaemia). Avoid potentially hazardous tasks (eg, driving or operating machinery) if patient experiences visual disturbance including blurred vision, dizziness, somnolence, vertigo & other CNS disturbances. May impair fertility; not recommended in women attempting to conceive. Consider treatment w/drawal in women who have difficulties conceiving or who are undergoing infertility investigation. Adolescent. Elderly.
Sign Out
